Mixed Donor Chimerism after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome  by Ngwube, Alexander et al.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S206eS239S236319
Mixed Donor Chimerism after Allogeneic Transplant in
Patients with Wiskott-Aldrich Syndrome
Alexander Ngwube 1, Lisa Forbes 2, Robert A. Krance 3,
Malcolm Brenner 3, Helen E. Heslop 4, Kathryn Leung 1,
Imelda C. Hanson2, Ghadir Sasa 1, Howard Rosenblatt 5,
Ann M. Leen 4, William Shearer 2, Swati Naik 1, Nabil M. Ahmed 1,
Stephen Gottschalk 3, Carl Allen 1, Caridad Martinez 1. 1 Center
for Cell and Gene Therapy, Baylor College of Medicine, Texas
Children’s Hospital, Houston, TX; 2 Immunology, Allergy and
Rheumatology, Baylor College of Medicine, Texas Children’s
Hospital, Houston, TX; 3 Center for Cell and Gene Therapy, Baylor
College of Medicine, Houston Methodist Hospital and Texas
Children’s Hospital, Houston, TX; 4 Center for Cell and Gene
Therapy, Baylor College of Medicine, Texas Children’s Hospital,
Houston Methodist Hospital, Houston, TX; 5Department of
Allergy/Immunology, Baylor College of Medicine, Houston, TX
Background: Wiskott-Aldrich syndrome (WAS) is a rare X-
linked disorder characterized by a triad of immunodeﬁ-
ciency, eczema and thrombocytopenia. This is as a result of
mutation in the WASP gene that regulates actin polymeri-
zation in hematopoietic cells. Currently, stem cell transplant
(SCT) is the most reliable curative treatment with excellent
results for patients with HLA-matched family or unrelated
donors. However, mixed donor chimerism even in the
setting of full myeloablative regimens is still a signiﬁcant
problem since mixed chimerism affecting the myeloid
compartment may result in persistent thrombocytopenia.
Thus, identifying factors associated with mixed donor
chimerism after SCT in WAS patients is extremely
important.
Methods: We performed a retrospective chart review of
eleven children who underwent allogeneic transplant for
WAS to identify any factors (i.e. pretransplant health of the
patients, degree of thrombocytopenia, conditioning regimen,
infection, peri-transplant factors, TH2 ﬂare) that may be
associated with mixed donor chimerism.
Results: The median age at transplant was 16 months
(range 3-39) and the donor was MRD in 4, MUD in 5 and
MMUD in 2. All patients received bone marrow apart from
one who received cord. The mean WAS score was 2.7 (range
1-5) and diagnosis was conﬁrmed by genetic testing in all
patients. All were conditioned with myeloablative regimens.
Nine received busulfan, cyclophosphamide, Ara-C or ﬂu-
darabine and campath while 2 patients got busulfan,
cyclophosphamide and ATG. The median nucleated cell dose
from the marrow was 5.3 x 109/kg (range 3 to 7.9). The
median times to neutrophil and platelet engraftment were
22.5 (range 13-27) and 19 (range 17-31) days respectively.
The overall survival by Kaplan Meier analysis is 91%, 95%CI:
51%-99% at 2 year post transplant. Only one patient devel-
oped grade IV aGvHD and died on Day +99. Five of eleven
(45%) had mixed donor chimerism, (range: 7-50%). Of these
5 patients, 2 had normalization of the platelet count despite
the mixed chimerism, 2 had full donor chimerism after
receiving a second transplant with the same donor, and 1
remains transfusion dependent awaiting a 2nd transplant.
No statistically signiﬁcant difference was found between
WAS scores, donor type, conditioning, stem cell source, age
at transplant and mixed chimerism amongst the eleven
patients.
Conclusions: Although the overall survival of our patient
populationwasexcellent, it doesnot reﬂect auniformresult intermsof engraftment.Noneof ourperi-transplant parameters
are predictive of mixed chimerism or engraftment outcome.
More correlative work is needed to assess genotype-pheno-
type risk factors for engraftment as well as pre transplant
immunologic and disease states to better assess the risk of
mixed chimerism and guide interventions to promote en-
graftment.320
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Currently, in our environment, 50% of patients requiring
transplantation cannot undergo this procedure due to lack of
a donor.
Twenty patients with different pathologies Eleven patients
had graft acceptance (55%) with complete chimerism. Nine
(45%) patients had primary graft failure. Of the patients
subjected to HT as rescue in case of cord graft failure, it was
noted that 100% of the patients are alive after 40 months of
follow-up with a statistically signiﬁcant difference (p ¼ 0.02)
compared with those subjected to HT as the primary choice.
This case review describes HT as a therapeutic tool in chil-
dren without an available donor. Our objective was to
describe the clinical features, complications and deaths in a
series of children undergoing HT in the Instituto Nacional de
Pediatria (INP) since 2009.
We included all patients undergoing HT between July 2009
and November 2012 .
Conditioning was done with ﬂudarabine (30 mg/m2) for 2
days, anti-thymocyte globulin (1.5 mg/kg/day) for 3 days,
nodal radiotherapy (7 Gy) andmelphalan (70mg/m2/day) for
2 days. For graft vs. host disease (GVHD) prophylaxis, cyclo-
sporine (6 mg/kg/day) was used from day -1.
The method of CD34+ selection was contemplated for pa-
tients with immunodeﬁciency and CD3+ depletion for pa-
tients with oncology/hematology diseases.
For bivariate analysis of qualitative variables, c2and Student t
test were performed. OS and DFS curves were performed
with the Kaplan-Meier method using SPSS v.20.0. Differences
between the rates of OS or DFS based on cell dose, age,
gender, and paternal or maternal donor were made using the
log-rank test; p<0.05 was considered signiﬁcant.
Themedian of cells infused was as follows: CD34+ 10.9 x 106/
kg (range: 2 to 32 x 106/kg), CD3+ 14.2 x 105/kg and CD19+
3.4 x 105/kg.
11 patients achieved graft (55%) with complete chimerism.
Nine patients (45%) had primary graft failure. Of the 11 pa-
tients with complete chimerism, two patients had graft loss
due to relapse of ALL (at 4 and 12 months post-HT). In a third
case therewas loss of the graft due to cytomegalovirus (CMV)
at 21 months post-HT. Of the patients subjected to HT as
rescue in case of cord graft failure, it was noted that 100% of
the patients were alive at 40 months of follow-up with a
